Nanomerics Ltd.

Nanomerics Ltd. is a clinical-stage biopharmaceutical company based in London, United Kingdom. It was founded in 2010 by Prof Ijeoma Uchegbu and Prof Andreas Schätzlein, world-leading scientists who spun the company out of University College London (UCL), the University of Glasgow and the University of Strathclyde in order to commercialise proprietary molecular engineering know-how. The company describes itself as platform-driven, developing precision medicines that address serious medical need, with a focus on ophthalmology and central nervous system (CNS) conditions. The core of Nanomerics' technology is its proprietary Molecular Envelope Technology (MET) platform. MET is designed to enhance and repurpose known drugs — delivering more drug to the site of action, with improved activity and reduced side effects. According to the company, the platform has been validated across multiple drug classes. This validation has been recognised externally: Nanomerics won the King's Award for Enterprise: Innovation in 2024 and the Royal Society of Chemistry (RSC) Emerging Technologies Prize in 2019/20. Nanomerics operates a partnering and out-licensing model. Two CNS-targeted products have been out-licensed, including Envelta™ (NB127), a non-addictive analgesic intended for nose-to-brain delivery, which is partnered with Virpax Pharmaceuticals. The company has also initiated a collaboration with NIH NCATS to advance the MET platform for CNS indications. In 2023, its METfect non-viral gene delivery platform achieved 50–55% gene knockdown in the cerebral cortex via intranasal administration, extending the company's reach into genetic therapies alongside pharmaceutical APIs. As a private, clinical-stage company, Nanomerics positions itself at the intersection of academic science and clinical translation, with deep roots in university research and a stated track record in moving programmes toward the clinic. Its pipeline spans pharmaceutical APIs and genetic therapies, and its business model centres on proprietary platform technologies that can be applied across multiple drug classes and partnered with larger pharmaceutical organisations.

Nanomerics Ltd. was founded in 2010 by Prof Ijeoma Uchegbu and Prof Andreas Schätzlein. The company was spun out of University College London (UCL), the University of Glasgow and the University of Strathclyde, with the aim of commercialising proprietary molecular engineering know-how developed in academic research. This academic origin gave the company deep roots in university science and a stated track record in clinical translation. From its base in London, Nanomerics built its business around a single core technology: Molecular Envelope Technology (MET). MET is designed to enhance and repurpose known drugs, getting more drug to the site of action with improved activity and reduced side effects. Over time, the company reports that the platform has been validated across multiple drug classes, which underpins its strategy of developing precision medicines for ophthalmology and CNS conditions. The company's scientific work has received external recognition. It won the Royal Society of Chemistry (RSC) Emerging Technologies Prize in 2019/20, and in 2024 it received the King's Award for Enterprise: Innovation. These awards reflect the company's positioning as a clinical-stage innovator applying platform technologies to pharmaceutical APIs and genetic therapies. Nanomerics has pursued a partnering and out-licensing model rather than building a large internal commercial infrastructure. Two CNS-targeted products have been out-licensed, including Envelta™ (NB127), a non-addictive analgesic for nose-to-brain delivery, which is partnered with Virpax Pharmaceuticals. The company also initiated a collaboration with NIH NCATS to advance the MET platform for CNS indications. In 2023, Nanomerics expanded its technological scope with METfect, a non-viral gene delivery platform. According to the company, METfect achieved 50–55% gene knockdown in the cerebral cortex via intranasal administration, marking a step into genetic therapies alongside its existing pharmaceutical API work. As of the available evidence, Nanomerics remains an active, private, clinical-stage biopharmaceutical company headquartered in London.

• 2024

  Received the King's Award for Enterprise: Innovation.

• 2023

  METfect non-viral gene delivery platform achieves 50–55% gene knockdown in the cerebral cortex via intranasal administration.

• 2019

  Awarded the Royal Society of Chemistry (RSC) Emerging Technologies Prize.

• 2010

  Nanomerics Ltd. founded by Prof Ijeoma Uchegbu and Prof Andreas Schätzlein, spun out of UCL, University of Glasgow and University of Strathclyde.

Clinical-stage, platform-driven biopharmaceutical company developing precision medicines for ophthalmology and CNS conditions, with a partnering and out-licensing business model.

• Molecular Envelope Technology (MET) platform

  Proprietary platform that enhances and repurposes known drugs, delivering more drug to the site of action with improved activity and reduced side effects; validated across multiple drug classes.

• Envelta™ (NB127)

  A non-addictive analgesic for nose-to-brain delivery, out-licensed and partnered with Virpax Pharmaceuticals.

• METfect

  Non-viral gene delivery platform introduced in 2023; achieved 50–55% gene knockdown in the cerebral cortex via intranasal administration.

1. 1Nanomerics — Engineering Precision Medicinesnanomerics.com
2. 2Nanomerics Ltd. (United Kingdom) — Wikidatawikidata.org